Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Mayoral, Karina
- dc.contributor.author Lizano-Barrantes, Catalina
- dc.contributor.author Zamora, Víctor
- dc.contributor.author Pont Acuña, Àngels
- dc.contributor.author Miret, Carme
- dc.contributor.author Barrufet González, Cristina
- dc.contributor.author Caballero-Rabasco, María Araceli
- dc.contributor.author Praena-Crespo, Manuel
- dc.contributor.author Bercedo, Alberto
- dc.contributor.author Valdesoiro-Navarrete, Laura
- dc.contributor.author Guerra, María Teresa
- dc.contributor.author Pardo Cladellas, Yolanda
- dc.contributor.author Martínez Zapata, María José
- dc.contributor.author Garin Boronat, Olatz, 1979-
- dc.contributor.author Ferrer Forés, Maria Montserrat
- dc.contributor.author ARCA Group
- dc.date.accessioned 2023-11-28T07:12:24Z
- dc.date.available 2023-11-28T07:12:24Z
- dc.date.issued 2023
- dc.description.abstract Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo. Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model. Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21-689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (-0.12, -0.20- -0.05 and -0.23, -0.41- -0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44-1.36). Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment.
- dc.format.mimetype application/pdf
- dc.identifier.citation Mayoral K, Lizano-Barrantes C, Zamora V, Pont A, Miret C, Barrufet C, Caballero-Rabasco MA, Praena-Crespo M, Bercedo A, Valdesoiro-Navarrete L, Guerra MT, Pardo Y, Martínez Zapata MJ, Garin O, Ferrer M; ARCA Group. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev. 2023 Oct 18;32(170):230124. DOI: 10.1183/16000617.0124-2023
- dc.identifier.doi http://dx.doi.org/10.1183/16000617.0124-2023
- dc.identifier.issn 0905-9180
- dc.identifier.uri http://hdl.handle.net/10230/58403
- dc.language.iso eng
- dc.publisher European Respiratory Society
- dc.relation.ispartof Eur Respir Rev. 2023 Oct 18;32(170):230124
- dc.rights © The authors 2023. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0 (http://creativecommons.org/licenses/by-nc/4.0/). For commercial reproduction rights and permissions contact permissions@ersnet.org
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.other Febre del fenc
- dc.subject.other Rinitis
- dc.subject.other Asma infantil
- dc.title Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion